NEW YORK (GenomeWeb News) – The University of Amsterdam will work with GeneGo through the company's MetaMiner Metabolic Diseases project, GeneGo said today.
The MetaMiner program is aimed at studying human diseases by using 'omics data to study disease pathways and gene-disease associations, the company said.
Through the multi-year MetaMiner programs, GeneGo develops content and tools while members, such as the University of Amsterdam or pharmaceutical companies, direct the process, prioritize goals, and edit the disease pathways. Current MetaMiner projects include collaborations in oncology, cystic fibrosis, cardiovascular diseases, and stem cells.
Milka Sokolovic at the Academic Medical Center at the University of Amsterdam said in a statement that GeneGo's disease pathway reconstructions are "fundamentally important and required for the understanding of disease processes so we can find cures."
"This will be the first 'systems analysis' platform devoted specifically for metabolic diseases," GeneGo VP of Business Development Julie Bryant said in a statement. "We will start with the 'usual suspects' of type 2 diabetes and obesity and then move to other human diseases which significantly affect metabolism."